Preclinical characterization of the JAK/STAT inhibitor SGI-1252 on skeletal muscle function, morphology, and satellite cell content.

Jacob R SorensenJordan D FuquaMichael R DeyhleJacob ParmleyCaitlin SkousenChad R HancockAllen C ParcellRobert D Hyldahl

Published in: PloS one (2018)

Orally delivered SGI-1252 was well tolerated, attenuates skeletal muscle STAT3 activity, and increases satellite cell content in mouse gastrocnemius muscle, likely by inhibiting myogenic progression.

Keyphrases

skeletal muscle
cell therapy
insulin resistance
single cell
signaling pathway
cell proliferation
stem cells
adipose tissue